Next week, Massachusetts voters will have the opportunity to vote on the limited legalization of psychedelics.
The proposed law – Question 4 – would allow persons aged 21 and older to grow, possess, and use certain natural psychedelic substances in certain circumstances. The psychedelic substances allowed would be two substances found in mushrooms (psilocybin and psilocyn) and three substances found in plants (dimethyltryptamine, mescaline, and ibogaine). These substances could be purchased at an approved location for use under the supervision of a licensed facilitator. This proposed law would otherwise prohibit any retail sale of natural psychedelic substances. This proposed law would also provide for the regulation and taxation of these psychedelic substances.
There are strong opinions on both sides of the proposed law.
Proponents argue that limited legalization would allow us to more fully explore the potential benefits of psychedelics as a treatment for individuals with refractory psychiatric disorders, including PTSD and addiction. In addition, they argue that, compared to other schedule 1 controlled drugs, many psychedelics carry relatively low risk.
On the other side of the debate, opponents of the proposal question if we have enough evidence to support the mental health benefits of psychedelics and raise concerns about the risks associated with the use of psychedelic drugs. Furthermore, they point out that the legalization of psychedelics may be more likely to benefit investors interested in psychedelic start-ups than those with mental health challenges.
It’s complicated. This article from Boston.com explores both sides of the divide.
What’s the Evidence?
Phase 2 clinical trials support the efficacy of psilocybin-assisted therapy for treatment-resistant depression (TRD), major depressive disorder (MDD) and alcohol use disorder (AUD) and LSD for anxiety disorders. Phase 3 trials have reported efficacy for MDMA-assisted therapy for PTSD; however, earlier this year, the FDA rejected a new drug application for MDMA-assisted therapy for the treatment of PTSD, requesting an additional clinical trial.
At Mass General Hospital, the Center for the Neuroscience of Psychedelics is looking into a possible treatment that combines psychedelics and MDMA with psychotherapy for the treatment of PTSD in veterans.
Read More
King F, Nahlawi A, Stern TA. Talking to Your Patients About Psychedelics: Using an Informed Approach and Understanding Indications, Risks, and Benefits. Prim Care Companion CNS Disord. 2024 Oct 15;26(5):24f03783.
